Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Carmen Burkhardt"'
Autor:
Stefan Knackmuss, Sergej Kiprijanov, Carmen Burkhardt, Uwe Reusch, Eugene Zhukovsky, Ivica Fucek, Karin Hoffmann, Fabrice Le Gall, Melvyn Little, Mikaelle Le Gall
Publikováno v:
mAbs
To improve recruitment and activation of natural killer (NK) cells to lyse tumor cells, we isolated a human anti-CD16A antibody with similar affinity for the CD16A 158F/V allotypes, but no binding to the CD16B isoform. Using CD16A-targeting Fv domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80d5aa53c0ca53a98f30e515f867e4cc
https://doi.org/10.4161/mabs.28591
https://doi.org/10.4161/mabs.28591
Autor:
Karin Wieligmann, Frank-D. Böhmer, Olaf Zschörnig, Carsten Frank, Martin Zacharias, Jens Ringel, Carmen Burkhardt, Diana Imhof
Publikováno v:
Journal of Biological Chemistry. 279:11375-11383
The protein-tyrosine phosphatase SHP-1 is a negative regulator of multiple signal transduction pathways. We observed that SHP-1 effectively antagonized Src-dependent phosphorylations in HEK293 cells. This occurred by dephosphorylation of Src substrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac30f07aaf1c56dbdbb02031cf86e19d
https://doi.org/10.1074/jbc.m309096200
https://doi.org/10.1074/jbc.m309096200
Autor:
Jeannette Ginestet, Oliver Renn, Carmen Burkhardt, Henning P. Nielsen, Joanna Woodward, Michael Archer
Publikováno v:
Nature reviews. Drug discovery. 11(6)
1, the focus of innovative drug research and development (R&D) should be guided not only by medical need and commercial potential but also by using information analysis to identify the areas in which new science is creating therapeutic opportunities.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f1119c3ee7c05af4b89a037f861cd7f
https://pubmed.ncbi.nlm.nih.gov/22596254
https://pubmed.ncbi.nlm.nih.gov/22596254
Autor:
Heike Wieland, Kamal Fettis, Carmen Burkhardt, Florian Dehmel, Thomas Beckers, Heiko Julius, Thomas Stengel, Thomas Ciossek, Steffen Weinbrenner, Thomas Maier
Publikováno v:
Journal of medicinal chemistry. 51(13)
Inhibitors of histone deacetylases (HDAC) are currently developed for the treatment of cancer. These include compounds with a sulfur containing head group like depsipeptide, alkylthiols, thiocarboxylates, and trithiocarbonates with a carbonyl group i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c65ae0c261686122018426f450bb0d1
https://pubmed.ncbi.nlm.nih.gov/18558669
https://pubmed.ncbi.nlm.nih.gov/18558669
Autor:
Petra Gimmnich, Thomas Maier, Heike Wieland, Thomas Beckers, Thomas Ciossek, Carmen Burkhardt, Sanders Karl
Publikováno v:
International journal of cancer. 121(5)
Advanced second generation inhibitors of histone deacetylases (HDAC) are currently used in clinical development. This study aimed at comparing the pharmacological properties of selected second generation HDAC inhibitors with the hydroxamate and benza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4831ffbc36d48a0c3dc462df0147f316
https://pubmed.ncbi.nlm.nih.gov/17455259
https://pubmed.ncbi.nlm.nih.gov/17455259
Autor:
Carmen Burkhardt, Stefan Knackmuss, Uwe Reusch, Markus Eser, Eugene Zhukovsky, Kristina Ellwanger, Ivica Fucek, Fionnuala McAleese
Publikováno v:
Cancer Research. 74:2643-2643
To harness the cytotoxic capacity of T cells for the treatment of EGFRvIII+ cancers, we developed a humanized bispecific tetravalent antibody, with two binding sites for CD3 (or CD16A) and EGFRvIII, the EGFRvIII/CD3 (and EGFRvIII/CD16A) RECRUIT-TandA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b07e8ce0c57f6b82df7bdc65e6125a9
https://doi.org/10.1158/1538-7445.am2014-2643
https://doi.org/10.1158/1538-7445.am2014-2643
Autor:
Stefan Knackmuss, Claudia Wall, Uwe Reusch, Carmen Burkhardt, Eugene Zhukovsky, Ivica Fucek, Kristina Ellwanger
Publikováno v:
Journal of Clinical Oncology. 32:e19546-e19546
e19546 Background: AFM11 is a bispecific TandAb molecule that recruits T cells (via an anti-CD3 domain) to CD19+ tumor cells (via an anti-CD19 domain). Due to the lack of a relevant species, the no...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a505afa9dea14d07a3495f8b1c78288
https://doi.org/10.1200/jco.2014.32.15_suppl.e19546
https://doi.org/10.1200/jco.2014.32.15_suppl.e19546
Autor:
Suisheng Zhang, Carmen Burkhardt, Katrin Buder, Matthias Görlach, Bernhard Schlott, Frank Grosse
Publikováno v:
The Journal of biological chemistry. 277(1)
Nuclear DNA helicase II (NDH II), also designated RNA helicase A, is a multifunctional protein involved in transcription, RNA processing, and transport. Here we report that NDH II binds to F-actin. NDH II was partially purified from HeLa nuclear extr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dedee9bb6263b145122639146bb9ae85
https://pubmed.ncbi.nlm.nih.gov/11687588
https://pubmed.ncbi.nlm.nih.gov/11687588
Autor:
Martin Zacharias, Carmen Burkhardt
Publikováno v:
Nucleic acids research. 29(19)
Binding of monovalent and divalent cations to two adenine–adenine platform structures from the Tetrahymena group I intron ribozyme has been studied using continuum solvent models based on the generalised Born and the finite-difference Poisson–Bol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc311f18c25fbad70d36ebd80ed6448f
https://pubmed.ncbi.nlm.nih.gov/11574672
https://pubmed.ncbi.nlm.nih.gov/11574672
Autor:
Stefan Knackmuss, Kristina Ellwanger, Carmen Burkhardt, Melvyn Little, Uwe Reusch, Eugene Zhukovsky, Ivica Fucek, Markus Eser, Fionnuala McAleese
Publikováno v:
Blood. 122:4405-4405
To harness the potent tumor-killing capacity of T cells for the treatment of CD19+ malignancies, we developed a humanized bispecific tetravalent antibody, with two binding sites for CD3 and CD19, the CD19/CD3 RECRUIT-TandAb AFM11. CD19 is expressed f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaeb60ebb428bbfbc4bc2280e6d3ccb7
https://doi.org/10.1182/blood.v122.21.4405.4405
https://doi.org/10.1182/blood.v122.21.4405.4405